OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
The Decoder · rss · 2026-10-21
- OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind.
- The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems.
- Developing a new drug in the US takes 10-15 years on average. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research.
More from Venture
- Nadella: SaaS Will Collapse in the Agent Era — But One Rebuild Cost More Than 2 Years of Subscription — msharmas · 2026-10-21
- Overflow: an MCP endpoint that turns leftover LLM subscription usage into a GitHub issue marketplace — Nitjsefnie · 2026-10-21
- Rocket launches as an open app platform where indie builders list, verify and sell their apps — alexmacgregor__ · 2026-10-21
- NVIDIA Pours $10B Into Europe, Adds 14 Startup Investments in One Week — nvidia · 2026-10-21
- Vietnamese users auto-translate Chinese tutorials via browser plugin to learn this site — gefei55 · 2026-10-21
- AEO experiment: median DR of AI-cited sites is 86 across 1,329 sources — tibo_maker · 2026-10-21